Rispolept oral solution 1mg/ml 30ml — Made in Belgium — Free Delivery

Schizophrenia (acute and chronic) and other psychotic conditions with severe productive symptoms (hallucinations, delusions, thinking disorders, aggressiveness) and / or negative symptoms (emotional and social detachment, paucity of speech); to reduce affective symptoms (anxiety, fear, depression) in patients with schizoaffective disorders and schizophrenia; as a means of long-term maintenance therapy to prevent relapse in chronic schizophrenia; behavioral disorders in patients with dementia with symptoms of aggressiveness (verbal outbursts, physical abuse), behavioral disorders (anxiety, agitation) or with a predominance of psychotic symptoms; as an adjunct in the treatment of manic episodes in bipolar disorders (episodes are characterized by an increased, expansive or irritable mood, increased self-esteem, reduced need for sleep, accelerated speech, dispersion of thoughts, inability to concentrate and rejection of criticism, as well as antisocial or aggressive behavior.

For adults, the preparation is prescribed at an initial dose of 2 mg / day. on the 2nd day, the dose is increased to 4 mg / day in 1 or 2 doses. in the future, a maintenance dose of the preparation is individually set, which is usually 4-8 mg / day. at a dose above 10 mg / day, the effectiveness does not increase, but the risk of developing extrapyramidal disorders increases. the maximum daily dose is 16 mg. if there is a need for additional sedation, benzodiazepines can be added to rispolept therapy.

In elderly patients or in patients with severe impairment of liver and / or kidney function, the recommended initial dose is 0.5 mg 2 times a day, it can be increased to 1-2 mg 2 times a day.

Treatment of behavioral disorders in patients with dementia begins with a dose of 0.25 mg 2 times a day. The optimal dose for most patients is 0.5 mg 2 times a day, for some patients the effective dose may be increased to 1 mg 2 times a day. After reaching an effective dose, the patient can receive the preparation 1 time per day.

The recommended starting dose for bipolar disorder is 2 mg/day. The dose can be increased by 2 mg / day no more than every other day. The optimal dose for most patients is 2–6 mg/day.

Hypersensitivity to the preparation.

Most common - insomnia, agitation, anxiety, headache, less often - drowsiness, fatigue, dizziness, incoordination, constipation, dyspepsia, nausea or vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculation disorder, orgasmic disorder , urinary incontinence, rhinitis, skin rash and other allergic reactions. rispolept causes extrapyramidal symptoms much less frequently than classical antipsychotics, however, in some cases, extrapyramidal symptoms such as tremor, rigidity, hypersalivation, bradykinesia, akathisia, and acute dystonia may occur. these symptoms are usually mild and resolve with dose reduction and/or administration (if necessary) of antiparkinsonian agents. sometimes, when prescribing rispolept, orthostatic hypotension, reflex tachycardia or hypertension, slight neutropenia or thrombocytopenia were observed. rispolept can induce dose-dependent hyperprolactinemia, which can manifest as galactorrhea, gynecomastia, menstrual disorders and amenorrhea. during treatment with rispolept, an increase in body weight, the development of angioedema and an increase in the activity of liver enzymes were noted. cerebrovascular manifestations were noted mainly in elderly patients. hyperglycemia and progression of diabetes mellitus have been reported in very rare cases. as with the use of classical antipsychotics, but to a much lesser extent, patients with schizophrenia observed: hyperhydration due to polydyspepsia or syndrome of inappropriate secretion of antidiuretic hormone, tardive dyskinesia, neuroleptic malignant syndrome, thermoregulation disorders and convulsive seizures.

Orthostatic hypotension may occur during treatment, especially during the initial dose selection period. rispolept should be used with caution in patients with diseases of the cardiovascular system (heart failure, myocardial infarction, conduction disturbances), as well as in dehydration, hypovolemia or cerebrovascular disorders; while the dose should be increased gradually, in accordance with the recommendations. if arterial hypotension occurs, consideration should be given to reducing the dose.